C1q antibody blockade

C1q antibody blockade refers to the therapeutic or experimental inhibition of complement component 1q (C1q) using monoclonal antibodies or antibody fragments. C1q is the initiating protein of the classical complement pathway, playing a key role in immune complex clearance, synaptic pruning, and inflammatory cascades. In the context of transplantation, C1q+ macrophages have been shown to interact with CD8+ T cells via the Cr1l/NF-κB/Tox signaling axis to promote T cell exhaustion and maintain allograft tolerance. Blockade of C1q with specific antibodies can reverse this immunosuppressive state, leading to T cell proliferation and graft rejection. Clinically, anti-C1q antibodies (such as tanruprubart/ANX005 and vonaprument/ANX007) are being developed for autoimmune and neurodegenerative diseases, including Guillain-Barré syndrome, geographic atrophy, and warm autoimmune hemolytic anemia.

Other names

anti-C1q monoclonal antibodyanti-C-1q monoclonal antibodyanti-C 1q monoclonal antibodyC1q blockadeC-1q blockadeC 1q blockadeC1q inhibitionC-1q inhibitionC 1q inhibition